Results 1 to 10 of about 60,441 (347)

Prevalence, patterns, and predictors of prescribing medications for opioid use disorder (MOUD) in the Inpatient setting [PDF]

Drug and Alcohol Dependence Reports
Background: There are many barriers to prescribing medications for opioid use disorder (MOUD). This study evaluates the prevalence, patterns, and predictors of inpatient MOUD prescribing at discharge to patients with a diagnosis of opioid use/opioid use ...
Ashley Burke, Nina Vadiei, Lea Mollon
doaj   +3 more sources

Opioid use Disorder for Prescription Opioid Medications

Global Journal of Addiction & Rehabilitation Medicine, 2017
Why are opioid medications prescribed in large quantities and high frequency when there is little or no proven efficacy for their therapeutic value? Why are opioids the most commonly prescribed medication in the United States for the past decades when the adverse consequences continue to grow and mount?
Norman S. Miller
openalex   +2 more sources

Development of an integrated digital health intervention to promote engagement in and adherence to medication for opioid use disorder [PDF]

Addiction Science & Clinical Practice, 2020
Background Buprenorphine-naloxone is an evidence-based treatment for Opioid Use Disorder. However, despite its efficacy, nearly half of participants are unsuccessful in achieving stabilization (i.e., period of time following medication induction in which
Kirsten J. Langdon, Susan Ramsey, Caroline Scherzer, Kate Carey, Megan L. Ranney, Josiah Rich   +5 more
doaj   +2 more sources

Prescribers’ satisfaction with delivering medications for opioid use disorder [PDF]

Substance Abuse Treatment, Prevention, and Policy, 2021
Background Expanding access to medications for opioid use disorder (MOUD), such as buprenorphine and extended release (XR) naltrexone, is critical to addressing the US opioid epidemic, but little is known about prescriber satisfaction with delivering ...
Hannah K. Knudsen, Randy Brown, Nora Jacobson, Julie Horst, Jee-Seon Kim, Hanna Kim, Lynn M. Madden, Eric Haram, Todd Molfenter   +8 more
doaj   +5 more sources

Medication-assisted recovery for opioid use disorder: A guide [PDF]

The Journal of Family Practice, 2023
Considering offering medical intervention for OUD to reduce mortality? It's essential to understand the clinical benefits, limitations, and regulation of available agents.
Jennie B. Jarrett
openalex   +3 more sources

Perspectives of substance use disorder counselors on the benefits and drawbacks of medications for opioid use disorder [PDF]

Addiction Science & Clinical Practice
Background Medications for opioid use disorder (MOUD) are among the best tools available to combat the opioid epidemic. Yet, use of MOUD among people with opioid use disorder (OUD) remains low.
Nicholas C. Cardamone, Rebecca E. Stewart, Kyle M. Kampman, Steven C. Marcus   +3 more
doaj   +2 more sources

Improving Surveillance of Hepatitis C Infections Among Patients Receiving Medication Treatment for Opioid Use Disorder [PDF]

, 2020
Background: Despite harm reduction efforts, Hepatitis C virus (HCV) infections among individuals with opioid use disorder tripled between 2010 and 2015 in the US.
Jacqueline Bray
openalex   +3 more sources

Leveraging pharmacy partnerships and Grant funding to improve access to medications for opioid use disorder [PDF]

Exploratory Research in Clinical and Social Pharmacy
Background: Increased availability and access to FDA-approved medications for opioid use disorder (MOUD) can improve efforts to address the ongoing opioid public health crisis.
John M. Vasko, Erin Shirley Orey, Carolanne Wartman, James K. Rowlett, Jefferson D. Parker, Donna M. Platt, Julie A. Schumacher   +6 more
doaj   +2 more sources

A mixed-method exploratory assessment of provider-based stigma of opioid use disorder (OUD) and support for medications for opioid use disorder (MOUD) in carceral settings [PDF]

Harm Reduction Journal
Background In 2019, the state of Maryland passed legislation requiring local detention centers to offer medications for opioid use disorder (MOUD) to all incarcerated individuals who met criteria for opioid use disorder (OUD).
Katherine J. McLean, Nathan E. Kruis, Eric Weintraub, Heather Fitzsimons, Christopher Welsh, Natalie Spicyn, Brook Kearley, William Altekruse, Nicholas Rowland, Annabelle Belcher   +9 more
doaj   +2 more sources

Trends in Access to Medications for Opioid Use Disorder.

JAMA Health Forum
ImportanceMedicaid, the largest payer for medications for opioid use disorder (MOUD), disenrolled more than 19.1 million individuals by March 2024 after the continuous coverage requirement ended in April 2023—a process termed Medicaid unwinding—but the impact on buprenorphine receipt remains unknown.ObjectiveTo assess the association between Medicaid ...
Gupta S, James A, Miles J, Samples H, Crystal S, Simon K.   +5 more
europepmc   +3 more sources